Pages that link to "Q33404547"
Jump to navigation
Jump to search
The following pages link to Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis (Q33404547):
Displaying 9 items.
- Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment (Q26998914) (← links)
- Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients. (Q33418378) (← links)
- Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis (Q35118673) (← links)
- Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan (Q35562209) (← links)
- Lethal acute liver failure in a patient treated with sunitinib (Q35942507) (← links)
- A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate (Q36262416) (← links)
- Dermatological toxicity associated with targeted therapies in cancer: optimal management (Q38239381) (← links)
- Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors (Q38948950) (← links)
- Sunitinib in kidney cancer: 10 years of experience and development. (Q39038214) (← links)